Xu Y, Ni F, Sun D, Peng Y, Zhao Y, Wu X
Adv Sci (Weinh). 2023; 11(6):e2307271.
PMID: 38072640
PMC: 10853751.
DOI: 10.1002/advs.202307271.
Tan X, Li J, Chen H, Luo W, Jiang N, Wang Z
World J Clin Cases. 2023; 11(7):1498-1505.
PMID: 36926405
PMC: 10011996.
DOI: 10.12998/wjcc.v11.i7.1498.
Khelwatty S, Puvanenthiran S, Essapen S, Bagwan I, Seddon A, Modjtahedi H
Cancers (Basel). 2021; 13(4).
PMID: 33562755
PMC: 7914886.
DOI: 10.3390/cancers13040638.
Bendell J, Sauri T, Gracian A, Alvarez R, Lopez-Lopez C, Garcia-Alfonso P
Oncologist. 2020; 25(3):e451-e459.
PMID: 32162804
PMC: 7066709.
DOI: 10.1634/theoncologist.2019-0291.
Hendricks A, Rosenstiel P, Hinz S, Burmeister G, Rocken C, Boersch K
BMC Med Genet. 2020; 21(1):3.
PMID: 31900123
PMC: 6942307.
DOI: 10.1186/s12881-019-0941-5.
Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer.
Liu F, Ren C, Jin Y, Xi S, He C, Wang F
Virchows Arch. 2019; 476(3):391-398.
PMID: 31720832
PMC: 7085476.
DOI: 10.1007/s00428-019-02668-9.
Therapeutic Suppression of miR-4261 Attenuates Colorectal Cancer by Targeting MCC.
Jiao G, Huang Q, Hu M, Liang X, Li F, Lan C
Mol Ther Nucleic Acids. 2017; 8:36-45.
PMID: 28918036
PMC: 5480279.
DOI: 10.1016/j.omtn.2017.05.010.
Detailed simulation of cancer exome sequencing data reveals differences and common limitations of variant callers.
Hofmann A, Behr J, Singer J, Kuipers J, Beisel C, Schraml P
BMC Bioinformatics. 2017; 18(1):8.
PMID: 28049408
PMC: 5209852.
DOI: 10.1186/s12859-016-1417-7.
ING4 suppresses tumor angiogenesis and functions as a prognostic marker in human colorectal cancer.
Chen Y, Huang Y, Hou P, Zhang Z, Zhang Y, Wang W
Oncotarget. 2016; 7(48):79017-79031.
PMID: 27806345
PMC: 5346695.
DOI: 10.18632/oncotarget.12984.
Geijigajakyak decoction inhibits the motility and tumorigenesis of colorectal cancer cells.
Lee S, Bae J, Ko Y, Lee K, Kim H, Kim K
BMC Complement Altern Med. 2016; 16(1):288.
PMID: 27527352
PMC: 4986256.
DOI: 10.1186/s12906-016-1281-z.
Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy.
Donnard E, Asprino P, Correa B, Bettoni F, Koyama F, Navarro F
Oncotarget. 2014; 5(19):9199-213.
PMID: 25193853
PMC: 4253428.
DOI: 10.18632/oncotarget.2374.
Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC.
Steinestel K, Lennerz J, Eder S, Kraft K, Arndt A
Virchows Arch. 2014; 465(2):155-63.
PMID: 24915895
DOI: 10.1007/s00428-014-1604-8.
The molecular genetics of colorectal cancer.
Ewing I, Hurley J, Josephides E, Millar A
Frontline Gastroenterol. 2014; 5(1):26-30.
PMID: 24416503
PMC: 3880905.
DOI: 10.1136/flgastro-2013-100329.
Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A.
Lotti F, Jarrar A, Pai R, Hitomi M, Lathia J, Mace A
J Exp Med. 2013; 210(13):2851-72.
PMID: 24323355
PMC: 3865474.
DOI: 10.1084/jem.20131195.
[Abelson interactor 1 (Abi1) in colorectal cancer. From synaptic plasticity to tumor cell migration].
Steinestel K, Glasle F, Bruderlein S, Steinestel J, Propper C, Moller P
Pathologe. 2013; 34 Suppl 2:189-94.
PMID: 24196611
DOI: 10.1007/s00292-013-1810-1.
Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.
Zhao C, Feng Q, Dou Z, Yuan W, Sui C, Zhang X
PLoS One. 2013; 8(9):e73860.
PMID: 24040096
PMC: 3770687.
DOI: 10.1371/journal.pone.0073860.
A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial.
Glockzin G, Rochon J, Arnold D, Lang S, Klebl F, Zeman F
BMC Cancer. 2013; 13:67.
PMID: 23391248
PMC: 3575316.
DOI: 10.1186/1471-2407-13-67.
Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.
Klotz L, Eichhorn M, Schwarz B, Seeliger H, Angele M, Jauch K
Langenbecks Arch Surg. 2012; 397(4):569-78.
PMID: 22415155
DOI: 10.1007/s00423-012-0946-4.
Opposite effects of tissue inhibitor of metalloproteinases-1 (TIMP-1) over-expression and knockdown on colorectal liver metastases.
Bandapalli O, Paul E, Schirmacher P, Brand K
BMC Res Notes. 2012; 5:14.
PMID: 22230683
PMC: 3284431.
DOI: 10.1186/1756-0500-5-14.
Cancer immunotherapy: Progress and challenges in the clinical setting.
Zarour H, Ferrone S
Eur J Immunol. 2011; 41(6):1510-5.
PMID: 21618503
PMC: 3426035.
DOI: 10.1002/eji.201190035.